<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 19-year-old man was diagnosed as having severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and received high-dose <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> treatment without hematological response </plain></SENT>
<SENT sid="1" pm="."><plain>A second course of high-dose mPSL treatment together with granulocyte colony-stimulating factor (G-CSF) plus erythropoietin (EPO) was then started and resulted in trilineage blood cell response </plain></SENT>
<SENT sid="2" pm="."><plain>Ten months after the combination therapy <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> developed and cytogenetic analysis showed 45,XX,-7, indicating an evolution to <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) associated with <z:mp ids='MP_0004026'>monosomy</z:mp> 7.G-CSF and EPO treatment together with immunosuppression may be an effective therapy in SAA patients, but such a therapy may increase the risk of evolution to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>